<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4990">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071602</url>
  </required_header>
  <id_info>
    <org_study_id>12-006317</org_study_id>
    <nct_id>NCT02071602</nct_id>
  </id_info>
  <brief_title>CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study</brief_title>
  <acronym>BELIEVE III</acronym>
  <official_title>CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint is to assess the safety and tolerability of CD-NP with the incidence of
      symptomatic hypotension being one of the key safety variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a &quot;proof of concept&quot;, randomized, double-blind, placebo controlled study. The study
      population will include 60 patients admitted with a first time ST elevation anterior STEMI
      as diagnosed by the following criteria: a) Significant chest discomfort and /or shortness of
      breath; b) ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial
      leads; c) Successful reperfusion therapy (&gt;TIMI grade 2 flow) either with thrombolytics or
      PTCA within 24 hours of onset of symptoms as documented by coronary angiography; and d) No
      previous history of an anterior AMI or previous ECG suggesting an old anterior AMI.

      Patients will be randomized to one of two doses of CD-NP (5 ng/kg/min and 10 ng/kg/min) or
      placebo continuous infusion for up to 72 hours in a 1:1:1 manner. All patients will receive
      other standard medical therapies as determined appropriate by the physician and in
      accordance to the ACC/AHA guidelines
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with symptomatic hypotension</measure>
    <time_frame>baseline to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of LV function improvement between placebo vs. CD-NP groups</measure>
    <time_frame>baseline to 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analyses of Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anterior ST-Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infused for up to 72 hours IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD-NP 5 ng/kg/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CD-NP 5 ng/kg/min infused for up to 72 hours IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD-NP 10 ng/kg/min</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CD-NP 10 ng/kg/min infused for up to 72 hours IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>Randomized 1:1:1</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>CD-NP 5 ng/kg/min</arm_group_label>
    <arm_group_label>CD-NP 10 ng/kg/min</arm_group_label>
    <other_name>Cenderitide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first time ST elevation anterior STEMI

          -  Significant chest discomfort and /or shortness of breath

          -  ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads

          -  Successful reperfusion therapy (&gt;TIMI grade 2 flow) either with thrombolytics or PTCA
             within 24 hours of onset of symptoms as documented by coronary angiography

          -  No previous history of an anterior AMI or previous ECG suggesting an  old anterior
             AMI.

        Exclusion Criteria:

          -  Cardiogenic shock, acute heart failure or hypotension (Systolic BP &lt; 90 mmHg)

          -  Previous MI

          -  Previous known decreased EF &lt; 40%

          -  Atrial Fibrillation

          -  Persistent signs and symptoms of Post MI ischemia

          -  Requirement of pressors for maintenance of blood pressure.

          -  Intra-aortic blood pump use

          -  Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or
             obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary
             hypertension.

          -  Severe congenital heart diseases

          -  Sustained ventricular tachycardia or ventricular fibrillation

          -  Second or third degree heart block without a permanent cardiac pacemaker

          -  Stroke within 3 months or other evidence of significantly compromised CNS perfusion

          -  Total bilirubin of &gt; 2.5 mg/dL or other liver enzymes &gt;2.5 times the upper limit of
             normal

          -  Patients with calculated GFR &lt;30 ml by MDRD equation or those with acute kidney
             injury as defined by an increase of plasma creatinine of 0.5 mg/dL from a plasma
             creatinine measured within the last 7 days

          -  Serum sodium of &lt; 125 mEq/dL or &gt; 160 mEq/dL

          -  Serum potassium of &lt; 3.0 mEq/dL or &gt; 5.8 mEq/dL

          -  Hemoglobin &lt; 8.5 gm/dl

          -  Other acute or chronic medical conditions or laboratory abnormality which may
             increase the risks associated with study participation or may interfere with
             interpretation of the data

          -  Received an investigational drug within 1 month prior to dosing

          -  Female subject who is pregnant or breastfeeding

          -  Unable to undergo cardiac MRI

          -  In the opinion of the investigator, is unlikely to comply with the study protocol or
             is unsuitable for any reasons
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Schirger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn E Polk, RN</last_name>
    <phone>507-255-2527</phone>
    <email>polk.lynn@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy M Woltman, RN</last_name>
    <phone>507-266-4095</phone>
    <email>woltman.cindy@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 22, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John A. Schirger</investigator_full_name>
    <investigator_title>Princpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart attack</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
